Literature DB >> 9552086

Predictors of adverse outcome in cancer patients with candidemia.

E J Anaissie1, J H Rex, O Uzun, S Vartivarian.   

Abstract

BACKGROUND: Many factors, including severity of illness, neutropenia, intravenous catheter management, and drug therapy may affect the outcome of candidemia in cancer patients.
METHODS: The records of all patients at M. D. Anderson Cancer Center who developed one or more positive blood cultures for Candida spp between January 1, 1988, and December 31, 1992, were retrospectively reviewed. Four hundred ninety-one episodes of candidemia were identified, for which 476 had complete medical records, which were reviewed in detail.
RESULTS: By 3-month follow-up, 52% of the patients had died. Neutropenia, higher APACHE III score, and visceral dissemination were associated with poor prognosis. Cure rates, adjusted for severity of illness, were similar for fluconazole and amphotericin B treatment. Exchange of central venous catheters was associated with a modest improvement in prognosis.
CONCLUSION: Several factors that influence the outcome of candidemia in cancer patients have been identified. These factors may be relevant for the clinical management of cancer patients with candidemia, and for the design of therapeutic trials.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9552086     DOI: 10.1016/s0002-9343(98)00030-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  58 in total

1.  Non-albicans Candida species isolated from plastic devices.

Authors:  E Dorko; M Kmet'ová; A Marossy; F Dorko; M Molokácová
Journal:  Mycopathologia       Date:  1999-12       Impact factor: 2.574

2.  Emerging Issues in Nosocomial Fungal Infections.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-10       Impact factor: 3.725

3.  Therapeutic Approach to Candida Sepsis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

Review 4.  Infections associated with medical devices: pathogenesis, management and prophylaxis.

Authors:  Christof von Eiff; Bernd Jansen; Wolfgang Kohnen; Karsten Becker
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Oral nystatin as antifungal prophylaxis in critically ill patients: an old SDD tool to be renewed?

Authors:  Philippe Eggimann; Michel Wolff; Jorge Garbino
Journal:  Intensive Care Med       Date:  2005-09-30       Impact factor: 17.440

6.  The Ess1 prolyl isomerase is required for growth and morphogenetic switching in Candida albicans.

Authors:  Gina Devasahayam; Vishnu Chaturvedi; Steven D Hanes
Journal:  Genetics       Date:  2002-01       Impact factor: 4.562

Review 7.  Candida infections of medical devices.

Authors:  Erna M Kojic; Rabih O Darouiche
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

8.  Development and characterization of an in vivo central venous catheter Candida albicans biofilm model.

Authors:  D Andes; J Nett; P Oschel; R Albrecht; K Marchillo; A Pitula
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

9.  The Pathophysiology and Treatment of Candida Sepsis.

Authors:  Brad Spellberg; John E. Edwards
Journal:  Curr Infect Dis Rep       Date:  2002-10       Impact factor: 3.725

10.  Modified colorimetric assay for susceptibility testing of azole antifungal drugs against Candida species.

Authors:  Jian Chen; Zhe Wan; Ruoyu Li
Journal:  J Clin Microbiol       Date:  2004-04       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.